Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: This study was conducted to clarify the frequency of the BRAF mutation in primary melanomas and its correlation with clinicopathologic parameters. Methods: We analyzed the frequency of BRAF mutation in patients with primary cutaneous melanoma (n=58) or non-cutaneous one (n=27) by performing dual priming oligonucleotide-based multiplex real-time polymerase chain reaction to isolate and to purify the DNA from the formalin-fixed and paraffin-embedded tumors. Results: The BRAF mutation was found in 17.2% (10/58) of patients with primary cutaneous melanoma and 11.1% (3/27) of those with non-cutaneous melanoma. The frequency of BRAF mutation was not correlated with any clinicopathologic parameters with the exception of the patient age. The frequency of the BRAF mutation was significantly higher in patients younger than 60 years as compared with those older than 60 years (p=0.005). Conclusions: Compared with previous reports, our results showed that the frequency of the BRAF mutation was relatively lower in patients with primary cutaneous melanoma. Besides, our results also showed that the frequency of the BRAF mutation had an inverse correlation with the age. Further studies are warranted to exclude methodological bias, to elucidate the difference in the frequency of the BRAF mutation from the previous reports from a Caucasian population and to provide an improved understanding of the molecular pathogenesis of malignant melanoma.
Abstract
Background: This study was conducted to clarify the frequency of the BRAF mutation in primary melanomas and its correlation with clinicopathologic parameters. Methods: We analyzed the frequency of BRAF mutation in patients with primary cutaneous melanoma (n=58) or non-cutaneous one (n=27) by performing dual priming oligonucleotide-based multiplex real-time polymerase chain reaction to isolate and to purify the DNA from the formalin-fixed and paraffin-embedded tumors. Results: The BRAF mutation was found in 17.2% (10/58) of patients with primary cutaneous melanoma and 11.1% (3/27) of those with non-cutaneous melanoma. The frequency of BRAF mutation was not correlated with any clinicopathologic parameters with the exception of the patient age. The frequency of the BRAF mutation was significantly higher in patients younger than 60 years as compared with those older than 60 years (p=0.005). Conclusions: Compared with previous reports, our results showed that the frequency of the BRAF mutation was relatively lower in patients with primary cutaneous melanoma. Besides, our results also showed that the frequency of the BRAF mutation had an inverse correlation with the age. Further studies are warranted to exclude methodological bias, to elucidate the difference in the frequency of the BRAF mutation from the previous reports from a Caucasian population and to provide an improved understanding of the molecular pathogenesis of malignant melanoma.
참고문헌 (27)
- 김혜성, "Recent Trend in the Incidence of Premalignant and Malignant Skin Lesions in Korea between 1991 and 2006", Journal of Korean Medical Science, 25(6), pp.924~929 (2010), 대한의학회
- Miller AJ, "Melanoma", N Engl J Med, 355, pp.51~65 (2006)
- Chabner BA, "Biological basis for cancer treatment", Ann Intern Med, 118, pp.633~637 (1993)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Balch CM, "Final version of 2009 AJCC melanoma staging and classification", J Clin Oncol, 27, pp.6199~6206 (2009)
- Lang J, "Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes", J Invest Dermatol, 125, pp.575~579 (2005)
- Yazdi AS, "Mutations of the BRAF gene in benign and malignant melanocytic lesions", J Invest Dermatol, 121, pp.1160~1162 (2003)
- Saldanha G, "Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies", Clin Cancer Res, 12, pp.4499~4505 (2006)
- Qi RQ, "BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han", J Invest Dermatol, 131, pp.1129~1138 (2011)
- Edlundh-Rose E, "NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing", Melanoma Res, 16, pp.471~478 (2006)
- ) mutation in primary melanoma, "J Invest Dermatol", 2007, 900~905
- Maldonado JL, "Determinants of BRAF mutations in primary melanomas", J Natl Cancer Inst, 95, pp.1878~1890 (2003)
- Bauer J, "BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site", Pigment Cell Melanoma Res, 24, pp.345~351 (2011)
- Elwood JM, "Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure", Int J Cancer, 78, pp.276~280 (1998)
- Holman CD, "Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits", J Natl Cancer Inst, 76, pp.403~414 (1986)
- Omholt K, "NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression", Clin Cancer Res, 9, pp.6483~6488 (2003)
- Devitt B, "Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma", Pigment Cell Melanoma Res, 24, pp.666~672 (2011)
- Akslen LA, "BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival", J Invest Dermatol, 125, pp.312~317 (2005)
- Shinozaki M, "Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas", Clin Cancer Res, 10, pp.1753~1757 (2004)
- Houben R, "Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis", J Carcinog, 3, pp.6~ (2004)
- Wong CW, "BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs", J Clin Pathol, 58, pp.640~644 (2005)
- Cohen Y, "Lack of BRAF mutation in primary uveal melanoma", Invest Ophthalmol Vis Sci, 44, pp.2876~2878 (2003)
- Edmunds SC, "Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas", Br J Cancer, 88, pp.1403~1405 (2003)
- Curtin JA, "Somatic activation of KIT in distinct subtypes of melanoma", J Clin Oncol, 24, pp.4340~4346 (2006)
- Bastian BC, "Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin", Cancer Res, 60, pp.1968~1973 (2000)
- Takata M, "Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas", J Invest Dermatol, 125, pp.318~322 (2005)
- Russo AE, "Melanoma: molecular pathogenesis and emerging target therapies (Review)", Int J Oncol, 34, pp.1481~1489 (2009)